## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `ss-31-ibd`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/ss-31-ibd/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/ss-31-ibd/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/ss-31-ibd/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/ss-31-ibd/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/ss-31-ibd/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `ss-31-ibd` v2 · content_hash `2cec7035b8d3b7fd…` · thread_head genesis · 18 DIVs
- **thesis (c1):** Mitochondrial dysfunction contributes to epithelial barrier failure and oxidative stress in IBD tissue.
  - c4 [human/active] No published human trials test SS-31 in IBD patients.
  - c5 [human/active] Elamipretide received FDA approval in 2025 for Barth syndrome.
  - c3 [preclinical/active] DSS-induced colitis mouse models show SS-31 protects epithelial cells and lowers mucosal oxidative stress.
  - c2 [mechanistic/active] SS-31 binds cardiolipin to stabilize mitochondrial membranes and reduce ROS production.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/ss-31-ibd/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/ss-31-ibd/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `ss-31-ibd`
- **title:** SS-31 (Elamipretide) for IBD: Mitochondrial Repair Pathways in Crohn's and Colitis Research
- **url:** https://miscsubjects.com/a/ss-31-ibd
- **register:** source_ledger
- **updated:** 2026-07-17T02:42:05.212Z
- **tags:** peptide, matrix

## Body

## What's breaking down if you have IBD (Crohn's / colitis)

IBD involves ongoing inflammation in the gut lining. Epithelial cells in the intestine face repeated oxidative stress and energy shortfalls. Mitochondria inside those cells produce the ATP needed for barrier maintenance and repair. When mitochondria falter, reactive oxygen species rise, tight junctions loosen, and the barrier becomes more permeable. Immune cells then overreact to luminal contents, creating a cycle where breakdown outpaces repair. Mitochondrial dysfunction appears in both Crohn's and ulcerative colitis tissue samples. It contributes to cell death signals and slowed regeneration of the mucosa.

## Why SS-31 (Elamipretide) might help you

If mitochondrial energy failure sits at one layer of your IBD picture, SS-31 targets that layer directly. The peptide binds cardiolipin in the inner mitochondrial membrane. This binding stabilizes the membrane structure. Stabilized membranes reduce electron leakage and lower reactive oxygen species output. Lower ROS means less damage to nearby proteins and DNA. Less damage allows epithelial cells to maintain ATP levels for repair processes. If the problem layer includes oxidative stress driving inflammation, the mitochondrial stabilization step comes before broader immune signals. SS-31 is discussed for tissue repair pathways, not for masking symptoms or blocking inflammation signals downstream.

## How these fit together

Single-compound focus applies here. SS-31 maps to the mitochondrial layer. Other compounds studied in IBD research often address immune modulation or barrier peptides at different layers. When profiles include multiple agents, each targets a distinct degeneration step without overlap in primary action.

## What the evidence actually shows

No human clinical trials test SS-31 specifically in IBD patients (preclinical and mechanistic data only). Preclinical work in DSS-induced colitis mouse models reports improved outcomes including protected intestinal epithelial cells, reduced mucosal inflammation, and lowered oxidative stress markers (site summary from peptidesindex.com, tier: preclinical). Separate animal studies show SS-31 preserves mitochondrial function after inflammatory insults such as lipopolysaccharide exposure, with reduced ROS and maintained ATP in neural and other tissues (Zhao et al., 2019, mouse model, tier: preclinical). Human data exist for other indications: elamipretide received FDA approval in 2025 for Barth syndrome, a primary mitochondrial disorder (multiple reports, tier: human). Phase 2 trials in geographic atrophy and mitochondrial myopathy showed tolerability but mixed functional results (tier: human).

## What scientists say

Researchers describe SS-31 as a cardiolipin-targeting antioxidant that concentrates in mitochondria and limits cytochrome c release and permeability transition pore opening (Tung et al., 2025 review, mechanistic). Mitochondrial dysfunction is noted as a feature in IBD models, with altered fission/fusion dynamics in DSS colitis (Mancini et al., 2020, preclinical). Scientists emphasize that benefits in animal colitis models remain exploratory and require human confirmation.

## What people say on Reddit

Limited specific discussion of SS-31 for IBD appears on Reddit. General peptide communities mention mitochondrial peptides for energy or fatigue but rarely link SS-31 directly to colitis or Crohn's experiences (anecdotal tier, sparse).

## What people say on X

Posts on X focus on the 2025 FDA approval for Barth syndrome rather than IBD applications. Occasional mentions of mitochondrial peptides in longevity contexts occur, but no detailed user reports tie SS-31 to IBD symptom changes (anecdotal tier, minimal).

## What we do not know

Direct causation between SS-31 mitochondrial effects and IBD mucosal healing lacks human confirmation. Optimal duration, combination strategies, and long-term tissue outcomes in gut inflammation remain untested in controlled trials. Whether benefits seen in DSS mouse models translate to human Crohn's or colitis histology is unknown. Interaction with standard IBD therapies has no published data.

## Safety and limits

Human trials report mostly mild injection-site reactions (tier: human). Serious adverse events appear rare in studied populations. SS-31 remains investigational outside approved rare-disease uses. No data establish safety or efficacy for IBD. Research compounds carry regulatory limits on human use beyond approved indications.

## Claims (5)

- **c4** [human w=0.8] No published human trials test SS-31 in IBD patients.
  - who_claims: grok/grok-4.3
  - sources: s4
- **c5** [human w=0.8] Elamipretide received FDA approval in 2025 for Barth syndrome.
  - who_claims: grok/grok-4.3
  - sources: s5
- **c3** [preclinical w=0.5] DSS-induced colitis mouse models show SS-31 protects epithelial cells and lowers mucosal oxidative stress.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c1** [mechanistic w=0.3] Mitochondrial dysfunction contributes to epithelial barrier failure and oxidative stress in IBD tissue.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [mechanistic w=0.3] SS-31 binds cardiolipin to stabilize mitochondrial membranes and reduce ROS production.
  - who_claims: grok/grok-4.3
  - sources: s2

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/ss-31-ibd/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `fafb89ded98f9524`

### s1 · pubmed · ok
- title: Perturbed Mitochondrial Dynamics Is a Novel Feature of Colitis
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC7327843/
- summary: Links mitochondrial changes to DSS colitis model.
- quote: DSS-colitis revealed increased mRNA for molecules associated with mitochondrial fission...
- claim_ids: c1
- hash: `331cabe4a73207ff`

### s2 · pubmed · ok
- title: Elamipretide: A Review of Its Structure, Mechanism of Action...
- url: https://pmc.ncbi.nlm.nih.gov/articles/PMC11816484/
- summary: Details cardiolipin binding and ROS reduction.
- quote: This mitochondria-targeting tetrapeptide selectively binds cardiolipin...
- claim_ids: c2
- hash: `4f1f7441aab6f37f`

### s3 · other · ok
- title: SS-31: Revolutionary Mitochondrial Enhancement Peptide
- url: https://peptidesindex.com/peptide/ss-31/
- summary: Summarizes preclinical colitis findings.
- quote: SS-31 improves outcomes in DSS-induced colitis models by protecting intestinal epithelial cells and reducing mucosal inflammation and oxidative stress.
- claim_ids: c3
- hash: `8307cb12eb4dafb3`

### s4 · pubmed · ok
- title: Elamipretide (SS-31) improves mitochondrial dysfunction...
- url: https://pubmed.ncbi.nlm.nih.gov/31747905/
- summary: Mouse study on inflammation and mitochondria; no IBD human data.
- quote: These findings indicate that LPS-induced memory impairment can be attenuated...
- claim_ids: c4
- hash: `9377b8db07ea3281`

### s5 · news · ok
- title: FDA Approval Announcement for Elamipretide
- url: https://www.instagram.com/p/DQmV9RaCSEF/?hl=en
- summary: Reports 2025 approval for rare mitochondrial disease.
- quote: The FDA has officially approved SS-31 (elamipretide)... for the treatment of Barth syndrome
- claim_ids: c5
- hash: `fafb89ded98f9524`

## Provenance (2 model passes)
- chain valid: yes · head: `deacefb34aabe752`

- write · grok/grok-4.3 · 2026-06-29T23:53 · hash `ff5749d65447`
- voxel_divide · owner · 2026-07-17T02:42 · hash `deacefb34aab`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/ss-31-ibd/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/ss-31-ibd/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"ss-31-ibd","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest ss-31-ibd|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim ss-31-ibd|tier|assertion`
- **iMessage ask:** `ss-31-ibd|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `ss-31-ibd`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/ss-31-ibd/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/ss-31-ibd/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*